Persistence of immunity to conjugate and polysaccharide pneumococcal vaccines in frail, hospitalised older adults in long-term follow up

This publication has 35 references indexed in Scilit:

• A retrospective analysis of hospital discharge records forS. pneumoniaediseases in the elderly population of Florence, Italy, 2010–2012
  Human Vaccines & Immunotherapeutics, 2014
• Pneumococcal infection in adults: burden of disease
  Clinical Microbiology and Infection, 2014
• A Randomized Clinical Trial of the Immunogenicity of 7-Valent Pneumococcal Conjugate Vaccine Compared to 23-Valent Polysaccharide Vaccine in Frail, Hospitalized Elderly
  PLOS ONE, 2014
• Long-term Comparative Immunogenicity of Protein Conjugate and Free Polysaccharide Pneumococcal Vaccines in Chronic Obstructive Pulmonary Disease
  Clinical Infectious Diseases, 2012
• Antibody persistence ten years after first and second doses of 23-valent pneumococcal polysaccharide vaccine, and immunogenicity and safety of second and third doses in older adults
  Human Vaccines, 2011
• The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A
  Vaccine, 2011
• Safety and Antibody Response, Including Antibody Persistence for 5 Years, after Primary Vaccination or Revaccination with Pneumococcal Polysaccharide Vaccine in Middle‐Aged and Older Adults
  The Journal of Infectious Diseases, 2010
• Revaccination with a 23‐Valent Pneumococcal Polysaccharide Vaccine Induces Elevated and Persistent Functional Antibody Responses in Adults Aged ⩾65 Years
  The Journal of Infectious Diseases, 2010
• Immunogenicity of a 23-valent pneumococcal polysaccharide vaccine in elderly residents of a long-term care facility
  The Brazilian Journal of Infectious Diseases, 2007
• A MULTI-LABORATORY EVALUATION OF AN ENZYME-LINKED IMMUNOASSAY QUANTITATING HUMAN ANTIBODIES TOSTREPTOCOCCUS PNEUMONIAEPOLYSACCHARIDES
  Immunological Investigations, 2001